Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193

1.

N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort.

Cushman M, Judd SE, Howard VJ, Kissela B, Gutiérrez OM, Jenny NS, Ahmed A, Thacker EL, Zakai NA.

Stroke. 2014 Jun;45(6):1646-50. doi: 10.1161/STROKEAHA.114.004712. Epub 2014 Apr 22.

2.

Plasma natriuretic peptides and incidence of subtypes of ischemic stroke.

Berntsson J, Zia E, Borné Y, Melander O, Hedblad B, Engström G.

Cerebrovasc Dis. 2014;37(6):444-50. doi: 10.1159/000363279. Epub 2014 Jul 23.

PMID:
25060145
3.

N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).

Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, Lopes RD, McMurray JJ, Granger CB.

J Am Coll Cardiol. 2013 Jun 4;61(22):2274-84. doi: 10.1016/j.jacc.2012.11.082. Epub 2013 Apr 3.

4.

Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation.

Roldán V, Vílchez JA, Manzano-Fernández S, Jover E, Gálvez J, Puche CM, Valdés M, Vicente V, Lip GY, Marín F.

Stroke. 2014 Mar;45(3):696-701. doi: 10.1161/STROKEAHA.113.003338. Epub 2014 Feb 11.

5.

Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation.

Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, Bergmann A, Platonov PG, Hedblad B, Engström G, Wang TJ, Melander O.

J Am Coll Cardiol. 2010 Nov 16;56(21):1712-9. doi: 10.1016/j.jacc.2010.05.049.

6.

N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in a Japanese community: the Hisayama study.

Doi Y, Ninomiya T, Hata J, Hirakawa Y, Mukai N, Ikeda F, Fukuhara M, Iwase M, Kiyohara Y.

Arterioscler Thromb Vasc Biol. 2011 Dec;31(12):2997-3003. doi: 10.1161/ATVBAHA.111.223669. Epub 2011 Sep 15.

7.

N-terminal pro-B-type natriuretic peptide as a predictor of incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis: the effects of age, sex and ethnicity.

Patton KK, Heckbert SR, Alonso A, Bahrami H, Lima JA, Burke G, Kronmal RA.

Heart. 2013 Dec;99(24):1832-6. doi: 10.1136/heartjnl-2013-304724. Epub 2013 Oct 16.

PMID:
24131775
8.

N-terminal pro-B-type natriuretic peptide and the risk of stroke and transient ischaemic attack: the Rotterdam Study.

Portegies ML, Kavousi M, Leening MJ, Bos MJ, van den Meiracker AH, Hofman A, Franco OH, Koudstaal PJ, Ikram MA.

Eur J Neurol. 2015 Apr;22(4):695-701. doi: 10.1111/ene.12633. Epub 2015 Jan 9.

PMID:
25573143
9.

Atrial fibrillation is an independent determinant of increased NT-proBNP levels in outpatients with signs and symptoms of heart failure.

Jug B, Sebestjen M, Sabovic M, Pohar M, Keber I.

Wien Klin Wochenschr. 2009;121(21-22):700-6. doi: 10.1007/s00508-009-1269-5.

PMID:
19998011
10.

Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy.

Longstreth WT Jr, Kronmal RA, Thompson JL, Christenson RH, Levine SR, Gross R, Brey RL, Buchsbaum R, Elkind MS, Tirschwell DL, Seliger SL, Mohr JP, deFilippi CR.

Stroke. 2013 Mar;44(3):714-9. doi: 10.1161/STROKEAHA.112.675942. Epub 2013 Jan 22.

11.
12.

Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.

Sanders-van Wijk S, Maeder MT, Nietlispach F, Rickli H, Estlinbaum W, Erne P, Rickenbacher P, Peter M, Pfisterer MP, Brunner-La Rocca HP; TIME-CHF Investigators.

Circ Heart Fail. 2014 Jan;7(1):131-9. doi: 10.1161/CIRCHEARTFAILURE.113.000527. Epub 2013 Dec 18.

13.

N-terminal pro-B-type natriuretic peptide, left ventricular mass, and incident heart failure: Multi-Ethnic Study of Atherosclerosis.

Choi EY, Bahrami H, Wu CO, Greenland P, Cushman M, Daniels LB, Almeida AL, Yoneyama K, Opdahl A, Jain A, Criqui MH, Siscovick D, Darwin C, Maisel A, Bluemke DA, Lima JA.

Circ Heart Fail. 2012 Nov;5(6):727-34. doi: 10.1161/CIRCHEARTFAILURE.112.968701. Epub 2012 Oct 2.

14.

Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease.

Tuñón J, Blanco-Colio L, Cristóbal C, Tarín N, Higueras J, Huelmos A, Alonso J, Egido J, Asensio D, Lorenzo Ó, Mahíllo-Fernández I, Rodríguez-Artalejo F, Farré J, Martín-Ventura JL, López-Bescós L.

Am J Cardiol. 2014 Feb 1;113(3):434-40. doi: 10.1016/j.amjcard.2013.10.012. Epub 2013 Nov 7.

PMID:
24295549
15.

Left ventricular ejection fraction assessment in older adults: an adjunct to natriuretic peptide testing to identify risk of new-onset heart failure and cardiovascular death?

deFilippi CR, Christenson RH, Kop WJ, Gottdiener JS, Zhan M, Seliger SL.

J Am Coll Cardiol. 2011 Sep 27;58(14):1497-506. doi: 10.1016/j.jacc.2011.06.042.

16.

Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study.

Folsom AR, Nambi V, Bell EJ, Oluleye OW, Gottesman RF, Lutsey PL, Huxley RR, Ballantyne CM.

Stroke. 2013 Apr;44(4):961-7. doi: 10.1161/STROKEAHA.111.000173. Epub 2013 Mar 7.

17.

Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy.

Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Vinereanu D, Siegbahn A, Yusuf S, Wallentin L.

Circulation. 2012 Apr 3;125(13):1605-16. doi: 10.1161/CIRCULATIONAHA.111.038729. Epub 2012 Feb 28.

18.

Risk stratification in stable coronary artery disease: superiority of N-terminal pro B-type natriuretic peptide over high-sensitivity C-reactive protein, gamma-glutamyl transferase, and traditional risk factors.

Bode E, Wuppinger T, Bode T, Alber H, Ulmer H, Pachinger O, Mair J.

Coron Artery Dis. 2012 Mar;23(2):91-7. doi: 10.1097/MCA.0b013e32834f1165.

PMID:
22157356
19.

N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.

Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P.

JAMA. 2005 Apr 6;293(13):1609-16.

PMID:
15811980
20.

Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.

von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, Filippatos GS, Doehner W, Koehler F, Papassotiriou J, Kremastinos DT, Banasiak W, Struck J, Ponikowski P, Bergmann A, Anker SD.

J Am Coll Cardiol. 2007 Nov 13;50(20):1973-80. Epub 2007 Oct 29.

Items per page

Supplemental Content

Write to the Help Desk